Pre-hOspital Evaluation of Chest Pain Patients With sUspected Non ST-segment eLevation myocARdial Infarction Using the HEART-score With a Troponin Point-of-care Test

NCT ID: NCT04851418

Last Updated: 2021-04-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

650 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-01

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Overcrowding in the emergency department is an increasing problem in hospitals worldwide. Point-of-care Troponin (POC cTn) testing combined with a well investigated risk stratification tool (HEART-score) used in the ambulance may contribute to more rapidly diagnostics of ruling in or ruling out myocardial infarctions (MI) and subsequently reduce unnecessary hospital admissions, total admission time and costs. However, the applicability of the POC cTn and the HEART-score in the pre-hospital setting remains unclear. This study will evaluate this applicability.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Co-primary Objectives:

1. To evaluate the interobserver agreement of the HEART-score performed by ambulance personnel compared to the HEART-score performed by emergency physicians.
2. To evaluate the diagnostic performance of a strategy based on a pre-hospital HEART-score (with POC cTn testing) or combined with an adjuvant single hs-cTn test at the emergency department to rule-in or rule-out acute coronary syndrome (ACS).
3. To evaluate the diagnostic performance of (serial) POC cTn testing or combined with hs-cTn testing compared to (serial) hs-cTn testing to rule-in or rule-out MI.
4. To investigate the feasibility of using the pre-hospital HEART-score and POC cTn in the 0/1 hour algorithm to rule-out ACS.

Secondary Objectives:
5. To evaluate the occurrence of major adverse cardiac events (MACE) in all included patients with a follow up time of 30 days from first medical contact.
6. To evaluate the patient reported outcome measures (PROMs) in all chest pain patients transported to the hospital at baseline and at 30 days
7. To perform a cost-analysis of an early diagnostic strategy using the pre-hospital HEART-score

Study design: A prospective, observational, single multicentre study Study population: Total number of patients needed for analysis: n=650 Inclusion criteria: - All out-of-hospital chest pain patients visited by an ambulance

* Transportation to a hospital with working diagnosis NSTE-ACS
* Age ≥ 18 years Exclusion criteria: - Comatose state, hemodynamic instability or shock
* Electrocardiographic ST-segment elevation in the pre-hospital setting treated as STEMI
* No pre-hospital 12-lead electrocardiogram performed or available
* An obvious non-cardiac cause for the chest pain (trauma, etc.)
* Suspicion of aortic dissection or pulmonary embolism
* Cognitive impairment
* Pregnancy
* Suspicion of COVID-19 by ambulance

Study procedures: The HEART-score and the POC cTn will be calculated in all included patients in the pre-hospital phase. Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing. Outcomes of any pre-hospital study measurements (i.e. pre-hospital POC cTn results or calculated pre-hospital HEART-scores) are blinded to the physicians at the ED and will not affect usual care. According to current practice, all patients will be transported to the hospital for further evaluation. At the emergency department (ED) all included patients will undergo regular hs-cTn testing and HEART-score assessment performed by emergency physicians (standard care), and an extra venous blood sample will be drawn for this study. Additional cTn tests (POC and hs-cTn) will be performed in the laboratory.

Main study parameters/endpoints:

1. HEART-score agreement (interobserver variability between pre-hospital and in-hospital HEART-score assessment)
2. Final diagnosis of NSTE-ACS at discharge
3. Myocardial infarction at discharge

Secondary study parameters/endpoints:
4. Composite endpoint (cardiovascular mortality, myocardial infarction, urgent revascularisation) at 30 days
5. Angina frequency and stability, physical limitations, treatment satisfaction, quality-of-life, cardiac anxiety and depression (SAQ, PHQ-4)

Follow-up: Total follow-up duration is 30 days after initial presentation. Other demographic and clinical parameters at baseline will be taken into account.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: All patients will undergo a POC cTn test performed by ambulance personnel. In all patients, two venous blood samples will be drawn in the pre-hospital phase (1x) and at the emergency department (1x). Besides the minimal risks of performing a POC finger prick test, no other risks are involved with study participation. All patients will be asked to fill in questionnaires (i.e. SAQ, PHQ-4) at baseline and at follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Possible NSTE-ACS

All patients with a suspicion of non-ST-elevation acute coronary syndrome (NSTE-ACS) in the pre-hospital phase are eligible for inclusion. In all included patients, the POC cTn will be performed and the HEART-score will be calculated in the pre-hospital phase. Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing. Outcomes of both the POC cTn or the pre-hospital HEART-score will be blinded for the physicians at the emergency department (ED) and will not affect current treatment strategy. All patients with suspected NSTE-ACS will undergo hs-cTn testing and the HEART-score will also be calculated at the ED (T1, standard of care). Here, an additional venous blood sample will be drawn next to routine blood testing testing (T1).

Possible NSTE-ACS

Intervention Type DEVICE

As mentioned in the group description

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Possible NSTE-ACS

As mentioned in the group description

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Point of Care troponin I iSTAT Abbot

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All out-of-hospital chest pain patients visited by an ambulance
* Transportation to a hospital with working diagnosis NSTE-ACS
* Age ≥ 18 years

Exclusion Criteria

* Comatose state, hemodynamic instability or shock
* Electrocardiographic ST-segment elevation in the pre-hospital setting
* No pre-hospital 12-lead electrocardiogram performed or available
* An obvious non-cardiac cause for the chest pain (trauma, etc.)
* Suspicion of aortic dissection or pulmonary embolism
* Cognitive impairment
* Pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Diakonessenhuis, Utrecht

OTHER

Sponsor Role collaborator

Abbott

INDUSTRY

Sponsor Role collaborator

St. Antonius Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

J.M. ten Berg

Prof. Dr. J.M. ten Berg

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

HJ Houtgraaf, Dr.

Role: PRINCIPAL_INVESTIGATOR

Diakonessenhuis, Utrecht

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St Antonius Hospital

Nieuwegein, , Netherlands

Site Status RECRUITING

Diakonessenhuis Utrecht

Utrecht, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

JM ten Berg, Prof. Dr.

Role: CONTACT

+31883201232

J x Azzahhafi, MD

Role: CONTACT

0883201311

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

J Azzahhafi, MD

Role: primary

+31883201311

HJ Houtgraaf, MD PhD

Role: primary

+31882507500

References

Explore related publications, articles, or registry entries linked to this study.

Azzahhafi J, Chan Pin Yin DR, Epping M, Bofarid H, Rikken SA, Verhagen T, Boomars R, Radstok A, Houtgraaf J, Bikker A, Ten Berg JM. Pre-hospital evaluation of chest pain patients using the modified HEART-score: rationale and design. Future Cardiol. 2024 Apr 25;20(5-6):241-250. doi: 10.1080/14796678.2024.2356995. Epub 2024 Jun 28.

Reference Type DERIVED
PMID: 38940186 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL71897.100.19

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.